Company profile
STORM Therapeutics Limited
Harnessing the power of RNA modification
- Industry
- Biotechnology Research
- Employees
- 15
- Headquarters
- Cambridge
- Founded
- 2015
- Office locations
- 1
STORM Therapeutics Limited company summary
STORM Therapeutics Limited is a company in the Biotechnology Research industry, headquartered in Cambridge, founded in 2015. On LinkedIn the company has around 15 employees. Its listed specialties include RNA modifications, mass spectrometry, drug discovery, oncology, biotech.
What technology does STORM Therapeutics Limited use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About STORM Therapeutics Limited
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.
Specialties
Where is STORM Therapeutics Limited located?
STORM Therapeutics Limited lists 1 location.
Compare companies similar to STORM Therapeutics Limited
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
STORM Therapeutics Limited stormtherapeutics.com | Biotechnology Research | 15 | 2015 | Cambridge |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about STORM Therapeutics Limited
What does STORM Therapeutics Limited do?
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.
How many employees does STORM Therapeutics Limited have?
STORM Therapeutics Limited has around 15 employees on LinkedIn.
Where is STORM Therapeutics Limited headquartered?
STORM Therapeutics Limited is headquartered in Cambridge.
When was STORM Therapeutics Limited founded?
STORM Therapeutics Limited was founded in 2015.
Build a lead list from companies like STORM Therapeutics Limited
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.